


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.



NED = no evidence of disease

CMP = complete metabolic panel

¹ Consider use of Vanderbilt’s [ABCDE’s approach to cardiovascular health](#)

² Based on National Comprehensive Cancer Network (NCCN) guidelines

³ Based on [Center for Disease Control and Prevention \(CDC\) guidelines](#)

⁴ See [Physical Activity](#), [Nutrition](#), and [Tobacco Cessation](#) algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

⁵ Includes [breast](#), [cervical](#) (if appropriate), [colorectal](#), [liver](#), [lung](#), [pancreatic](#), [prostate](#), and [skin cancer screening](#)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- American Cancer Society. (2018). *American Cancer Society guidelines for the early detection of cancer*. Retrieved from <http://www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer>
- Bellizzi, K. M., Rowland, J. H., Arora, N. K., Hamilton, A. S., Miller, M. F., & Aziz, N. M. (2009). Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, 27(6), 960-966. doi:10.1200/JCO.2008.17.5026
- Centers for Disease Control and Prevention. (2020). *Recommended immunization schedule for adults aged 19 years or older, United States, 2020*. Retrieved from <https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>
- Ewer, M. S., & Ewer, S. M. (2009). Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data. *Journal of Clinical Oncology*, 27(36), 6073-6075. doi:10.1200/JCO.2009.25.5091
- Ewer, M. S., Von Hoff, D. D., & Benjamin, R. S. (2011). A historical perspective of anthracycline cardiotoxicity. *Heart Failure Clinics*, 7(3), 363-372. doi:10.1016/j.hfc.2011.03.001
- Hibberd, P. L. (2020). Immunizations in adults with cancer. *UpToDate*. Retrieved November 9, 2020, from <http://www.uptodate.com/contents/immunizations-in-patients-with-cancer>
- Kaplan, B., Kopyltsova, Y., Khokhar, A., Lam, F., & Bonagura, V. (2014). Rituximab and immune deficiency: Case series and review of the literature. *The Journal of Allergy and Clinical Immunology: In Practice*, 2(5), 594-600. doi:10.1016/j.jaip.2014.06.003
- Kim, D. K., Riley, L. E., & Hunter, P. (2018). Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2018. *Morbidity and Mortality Weekly Report – February 6, 2018*, 67(5), 158-160. doi:10.15585/mmwr.mm6705e3
- Lin, T. L., Kuo, M. C., Shih, L. Y., Dunn, P., Wang, P. N., Wu, J. H., . . . Lu, S. C. (2012). Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. *Annals of Hematology*, 91(11), 1741-1745. doi:10.1007/s00277-012-1508-0
- National Comprehensive Cancer Network. (2020). *Survivorship* (NCCN Guideline Version 2.2020). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf
- Ng, A. K., LaCasce, A., & Travis, L. B. (2011). Long-term complications of lymphoma and its treatment. *Journal of Clinical Oncology*, 29(14), 1885-1892. doi:10.1200/JCO.2010.32.8427
- Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., . . . Ladetto, M. (2015). Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 26(suppl 5), v116-v125. doi:10.1093/annonc/mdv304
- Vanderbilt Cardio-Oncology Program. (2017). *Know Your ABCDE's*. Retrieved from <http://www.cardioonc.org/2017/08/29/know-your-abcs/>

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Lymphoma Survivorship work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Sairah Ahmed, MD (Lymphoma/Myeloma)
Anjuly Bansal, BS, PA (Lymphoma/Myeloma)
Luis Fayad, MD (Lymphoma/Myeloma)
Olga N. Fleckenstein[♦]
Katherine Gilmore, MPH (Cancer Survivorship)
Fredrick Hagemeister, MD (Lymphoma/Myeloma)
Thoa Kazantsev, MSN, RN, OCN[♦]
Haleigh Mistry, MPAS, PA (Lymphoma/Myeloma)
Ellen Mullen, PHD, MSN, ANP, GNP (Lymphoma/Myeloma)
Alma Rodriguez, MD (Lymphoma/Myeloma)[‡]
Jason Westin, MD (Lymphoma/Myeloma)[‡]

[‡] Core Development Lead

[♦] Clinical Effectiveness Development Team